Reading UNCY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track UNCY free→Reading UNCY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track UNCY free→QuarterlyIQ Insights · UNCY
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. As previously reported, Unicycive Therapeutics, Inc. (the “Company”) entered into a Sales Agreement, dated November 13, 2024, with Guggenheim Securities, LLC, as sales agent (the “Agent”) as amended by Amendment No. 1 to Sales Agreement dated November 14, 2025, between the Company and the Agent (as amended, the “Sales Agreement”), to sell shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.